Voglibose

Voglibose

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A10BF03 ( WHO )
Identifiers
IUPAC name (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
CAS Number	83480-29-9  Y
PubChem CID	444020
DrugBank	DB04878  Y
ChemSpider	392046  Y
UNII	S77P977AG8
KEGG	D01665  Y
ChEMBL	ChEMBL476960  Y
CompTox Dashboard (EPA)	DTXSID2021442
Chemical and physical data
Formula	C10H21NO7
Molar mass	267.278 g·mol−1
3D model (JSmol)	Interactive image
SMILES OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
InChI InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 Y Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N Y
(verify)

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. ^[1] Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, ^[2] under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. ^[3]

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. ^[2]

There are three major drugs which belong to this class, acarbose, miglitol and voglibose, ^[2] of which voglibose is the newest.

Efficacy

A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). ^[4] It was found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction. ^[4]

References

1. Chen X, Zheng Y, Shen Y (2006). "Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors". Current Medicinal Chemistry. 13 (1): 109–116. doi:10.2174/092986706789803035. PMID   16457643.
2. Dabhi AS, Bhatt NR, Shah MJ (December 2013). "Voglibose: an alpha glucosidase inhibitor". Journal of Clinical and Diagnostic Research. 7 (12): 3023–3027. doi:10.7860/JCDR/2013/6373.3838. PMC   3919386 . PMID   24551718.
3. "Voglibose". AdisInsight. Springer Nature Switzerland AG.
4. Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA, et al. (Cochrane Metabolic and Endocrine Disorders Group) (December 2018). "Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 2018 (12) CD005061. doi:10.1002/14651858.CD005061.pub3. PMC   6517235 . PMID   30592787.

Further reading

• Miller CK (2004). "New therapeutic options in the treatment of diabetes mellitus". In Greenstein B (ed.). Clinical Pharmacology for nurses (17th ed.). Elsevier Limited, Churchill Livingstone.
• Wilson L (1997). Mehra IV (ed.). Managing the Patient with Type II Diabetes. Aspen Publishers. pp. 62–63. ISBN   978-0-8342-1018-9.